(NP (NP (DT The) (NN use)) (PP (IN of) (NP (JJ interferon-gamma-treated) (NN U937) (NNS cells))) (PP (IN in) (NP (NN chemiluminescence) (NNS assays))) (SBAR (WHNP-55 (-NONE- 0)) (S (NP-SBJ (-NONE- *T*-55)) (VP (TO to) (VP (VB detect) (NP (NP-COOD (NP (JJ red) (NN cell)) (, ,) (NP (NN platelet)) (CC and) (NP (NN granulocyte) (NNS antibodies))) (PP (IN of) (NP (JJ potential) (JJ clinical) (NN significance)))))))) (. .))
(S (NP-SBJ-56 (NP (DT The) (ADJP (ADJP (JJ chemiluminescent)) (PRN (-LRB- -LRB-) (ADJP (JJ CL)) (-RRB- -RRB-))) (NN response)) (PP (IN of) (NP (NP (NP (JJ interferon-gamma-treated) (NN U937)) (PRN (-LRB- -LRB-) (NP (NN IFN-U937)) (-RRB- -RRB-))) (NNS cells))) (PP (TO to) (NP (VBN sensitized) (NN target) (NNS cells)))) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (NP-57 (-NONE- *-56)) (S (NP-SBJ (-NONE- *-57)) (VP (TO to) (VP (VB detect) (NP-COOD (NP (JJ red) (NN cell)) (, ,) (NP (NN platelet)) (CC and) (NP (NN granulocyte) (NNS antibodies))))))))) (. .))
(S (NP-SBJ-58 (NP (DT A) (NN clone)) (PP (IN of) (NP (NN U937) (NNS cells))) (SBAR (-NONE- *ICH*-59))) (VP (VBD was) (VP (VBN selected) (NP (-NONE- *-58)) (SBAR-COOD-59 (SBAR (WHNP-60 (WDT which)) (S (NP-SBJ (-NONE- *T*-60)) (VP (VBD expressed) (NP (NP (NN Fc) (NN receptor) (NN I)) (PRN (-LRB- -LRB-) (NP (NN Fc) (NN gamma) (NN RI)) (-RRB- -RRB-)))))) (CC and) (SBAR (WHNP-61 (WDT which)) (, ,) (S (PP-TMP (IN after) (NP (NP (NN incubation)) (PP (IN with) (NP (NN IFN-gamma))) (PP-TMP (IN for) (NP (CD 72) (NN h))))) (, ,) (NP-SBJ-62 (-NONE- *T*-61)) (VP (VBD was) (ADJP-PRD (JJ capable) (PP (IN of) (S (NP-SBJ (-NONE- *-62)) (VP (VBG generating) (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (JJ lucigenin-enhanced) (NN CL)))))))))))))) (. .))
(S (NP-SBJ-63 (NP (DT The) (NN CL) (NNS responses)) (PP (IN of) (NP-COOD (NP (NN IFN-U937) (NNS cells)) (CC and) (NP (JJ peripheral) (NN blood) (JJ human) (NNS monocytes)))) (PP (TO to) (NP (VBN sensitized) (NP-COOD (NP (JJ red) (NNS cells)) (, ,) (NP (NNS platelets)) (CC or) (NP (NNS granulocytes)))))) (VP (VBD were) (ADVP (RB then)) (VP (VBN compared) (NP (-NONE- *-63)))) (. .))
(S (NP-SBJ (NP (NNS Assays)) (VP (VBG using) (NP-COOD (NP (NNS monocytes)) (CC or) (NP (NN IFN-U937) (NNS cells))))) (VP (VBD were) (PP-PRD (IN of) (NP (NP (JJ comparable) (NN sensitivity)) (PP (IN for) (NP (NP (NN detection)) (PP (IN of) (NP (NP (NNS antibodies)) (PP (IN against) (NP (NP (DT all) (CD three) (NNS types)) (PP (IN of) (NP (NN target) (NN cell)))))))))))) (. .))
(S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (NP (DT the) (NN use)) (PP (IN of) (NP (NN IFN-U937) (NNS cells)))) (VP-COOD (VP (VBD reduced) (NP (JJ interassay) (NN variation))) (CC and) (VP (VBD simplified) (NP (NN assay) (NN performance)))) (. .))
(S (NP-SBJ-64 (NP (DT The) (JJ potential) (JJ clinical) (NN usefulness)) (PP (IN of) (NP (DT these) (NN CL) (NNS assays)))) (VP (VBD was) (VP (VBN suggested) (NP (-NONE- *-64)) (PP (IN by) (NP-LGS (NP (DT the) (NN ability) (S (-NONE- *ICH*-65))) (PP (IN of) (NP-COOD (CC both) (NP (NNS monocytes)) (CC and) (NP (NN IFN-U937) (NNS cells)))) (S-65 (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB respond) (PP (TO to) (NP (NP-COOD (NP (JJ red) (NNS cells)) (, ,) (NP (NNS platelets)) (CC or) (NP (NNS granulocytes))) (VP (VBN sensitized) (NP (-NONE- *)) (PP (IN with) (NP (NP (NN sera)) (PP (IN from) (NP (NP (JJ pregnant) (NNS women)) (SBAR (WHNP-66 (WP$ whose) (NNS babies)) (S (NP-SBJ (-NONE- *T*-66)) (VP (VBD had) (NP-COOD (CC either) (NP (NP (JJ haemolytic) (NN disease) (IN of) (DT the) (JJ newborn)) (PRN (-LRB- -LRB-) (NP (NN HDN)) (-RRB- -RRB-))) (, ,) (NP (JJ alloimmune) (NN thrombocytopenia)) (CC or) (NP (JJ alloimmune) (NN neutropenia))) (ADVP (RB respectively))))))))))))))))))) (. .))
(S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (NP-COOD (NP (NNS monocytes)) (CC and) (NP (NN IFN-U937) (NNS cells))) (NP (DT both))) (VP (VBD responded) (PP (TO to) (NP (NP (JJ red) (NNS cells)) (VP (VBN sensitized) (NP (-NONE- *)) (PP (IN with) (NP (NP (NNS antibodies)) (PP (IN against) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (NNS specificities)) (PP (IN of) (NP (NP (ADJP-COOD (ADJP (VBN assumed)) (-LRB- -LRB-) (IN although) (ADJP (RB not) (VBN documented)) (-RRB- -RRB-)) (JJ clinical) (NN significance)) (PP (IN for) (NP (NN blood) (NN transfusion) (NNS recipients))))))))))))))) (. .))
(S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ-COOD (NP (NNS monocytes)) (CC and) (NP (NN IFN-U937) (NNS cells))) (VP (VBD responded) (ADVP (RB only) (RB weakly)) (PP (TO to) (NP (NP (JJ red) (NNS cells)) (VP (VBN sensitized) (NP (-NONE- *)) (PP-COOD (PP (IN with) (CC either) (NP (NP (JJ anti-D)) (PP (IN in) (NP (NP (NN sera)) (PP (IN from) (NP (NP (NNS mothers)) (PP (IN of) (NP (NP (NNS babies)) (VP (JJ unaffected) (NP (-NONE- *)) (PP (IN by) (NP-LGS (NN HDN)))))))))))) (, ,) (CC or) (PP (IN with) (NP (NP (NNS antisera)) (VP (VBG containing) (NP (NP (JJ high) (NN titre) (NNS antibodies)) (PP (IN with) (NP (NP (NNS specificities)) (VP (RB not) (ADVP (RB normally)) (VBN associated) (NP (-NONE- *)) (PP (IN with) (NP (ADJP (RB significantly) (VBN reduced)) (JJ red) (NN cell) (NN survival))))))))))))))) (. .))
